Patient access: Enhancing the referral process  by Cruz, E.D. et al.
regimen for patients. Prevention and/or reduction of mucositis
should start with the development of a standardized oral care
regimen that will be used consistently in the clinical management
of the patient. Mouth care protocols should also be simple and easy
to perform in order to ensure that patients will be compliant with
an oral care regimen. The goal is to determine the most effective
treatment available to prevent mucositis, treat the signs and symp-
toms of mucositis, and provide information to be used to develop
a new oral care standard for patients in the BMT unit at UAB.
Currently, all patients receiving a BMT at UAB regardless of their
diagnosis or chemotherapy regimen are placed on the same mouth
care protocol, which is to be used every four hours. This protocol
includes biotine, chlorhexadine, sucralfate, and nystatin. According
to the nurses in the BMT unit, patients do not consistently use the
mouth care provided. Patients complain that there are too many
steps involved, report an unpleasant taste, nausea, and anxiety
when it is time to do mouth care. During 2004, 12 out of 77
patients at UAB had grade 3 mucositis and 42 out of 77 had grade
2 mucositis. Recommendations were made for high- risk patients
(identiﬁed prior to receiving chemotherapy) to receive an aggres-
sive oral care protocol, including the use of palifermin. All low-risk
patients would receive saline rinses, or salt water and baking soda
solutions in order to prevent or treat mucositis.
470
VENO OCCULSIVE DISEASE: A POTENTIALLY LIFE THREATENING COM-
PLICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
Summers, E., Edmisten, J., Martin, P.L., Frey, M., Kurtzberg, J.
Pediatric Blood and Marrow Transplant Program at Duke University
Medical Center, Durham, NC.
Veno Occlusive disease (VOD) is a potentially life threatening
liver complication occurring in up to 5% of patients undergoing
hematopoietic stem cell transplantation (HSCT). It usually occurs
before day 35 post transplant and presents with signs and symp-
toms including painful hepatomegaly, jaundice, ﬂuid retention,
weight gain of 	5%, and ascites. Patients with VOD consume
platelets, are often refractory to platelet transfusions and become
coagulopathic. VOD occurs when the blood vessels of the liver
become swollen and congested, diminishing the liver’s ability to
remove toxins and waste from the blood. Fluids may build up in the
liver causing additional swelling and tenderness (Mullaly K., 2002).
Duke Low dose heparin infused continuously for the ﬁrst 28 days
post transplant  actigall can be used as prophylaxis against VOD.
Patients at high risk for VOD may be identiﬁed during the trans-
plant workup and include those with prior liver disease, iron
overload, decreased protein C, and heavily pretreated patients with
malignancies. An attempt is made to avoid the use of hepatotoxic
agents, but radiation, cytoxan, and busulfan are frequently neces-
sary to treat the patient’s underlying disease. The use of deﬁb-
rotide, an investigational agent with local thrombolytic activity,
appears to be a safe and effective treatment options for patients
with VOD. Studies have reported up to 50% of children respond-
ing favorably to treatment with deﬁbrotide when signiﬁcant VOD
has occurred. Nurses play an important role in diagnosing VOD in
pediatric patients by ﬁrst monitoring strict IOs, daily weights, and
pain reported by the patients on assessment. The purpose of this
poster is to: (1) describe the signs and symptoms of Veno Occlusive
disease; (2) state the treatment modalities currently used for treat-
ment and prevention of VOD; and (3) describe important aspects
of nursing care of the pediatric patient with VOD.
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THE DEVELOPMENT OF AN ALGORITHM MANAGING ACUTE DELIRIUM
IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
(SCT)
Shelburne, N.F., Simpson, K.K., Bevans, M.F. National Institutes of
Health, Clinical Center, Bethesda, MD.
Delirium is deﬁned as an acute and ﬂuctuating disruption of
attention and cognition that is not accounted for by preexisting
dementia. Fann et al (2002) reports that up to 50% of recipients
undergoing a SCT experience delirium. Pretreatment predictors of
delirium have been identiﬁed in oncology patients, which are
frequently present in SCT recipients, in addition to the direct and
indirect effects of their intense treatment. Negative outcomes as-
sociated with delirious behavior can include increased length of
stay, and injuries related to falls or other self inﬂicted behaviors.
Current literature focuses on the identiﬁcation of predictors and
reliable recognition of delirium. Minimal information is available
to guide the use of interventions to avoid negative consequences.
The purpose of this project was to develop a standardized approach
to improve the recognition of delirium, identify SCT patients at
high risk for delirium, and guide nursing interventions to decrease
complications.
The Delirium Intervention Algorithm was activated with 15
SCT inpatients during a 3-month time period, including 5 (33%)
myeloablative, and 10 (66%) nonmyeloablative. Three (20%) pa-
tients experienced acute delirium, and 9 (75%) were identiﬁed at
high risk for delirium. One (11%) high risk patient experienced a
fall. High risk patients experienced elevations in kidney and liver
function, narcotic and benzodiazepine use, and alterations in
mood/affect. The application of the Delirium Intervention Algo-
rithm improved the care of SCT patients by guiding nurses in the
early recognition of delirium, the identiﬁcation and removal of
contributing factors, and the use of interventions to ensure patient
safety and maintain dignity. Implementation of this standardized
approach to patient care empowers the nurse to effectively reduce
length of stay and morbidity in SCT recipients at risk for compli-
cations from delirium.
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STRONGYLOIDES STERCORALIS IN THE IMMUNOCOMPROMISED POP-
ULATION
Rivera, Z.R., Massaro, A. University of Texas M. D. Anderson Cancer
Center, Houston, TX.
Blood Marrow Transplant (BMT) patients are typically immu-
nocompromised for prolonged periods. Due to a compromised
immune system, BMT patients are susceptible to acquiring oppor-
tunistic infections. Infectious organisms may include parasites such
as Toxoplasma gondii, Pneumocystis carinii, Entamoeba coli, and more
infrequently Strongyloides stercoralis.
Strongyloides stercoralis is an intestinal nematode of humans esti-
mated affecting tens of millions of persons worldwide. This para-
site is endemic in tropical or temperate and subtropical climates.
Risk factors may include travel to those areas. S. stercoralis can
transform into a fulminant fatal illness in certain conditions asso-
ciated with a compromised host. With the increased mortality and
morbidity associated with S. stercoralis focusing on identifying,
screening, and treating those at risk is warranted. Of the individ-
uals who are infected with S. stercoralis, 50% are asymptomatic and
75% manifest eosinophilia. Clinical symptoms include epigastric
pain and tenderness, diarrhea, nausea and vomiting, constipation,
and weight loss. In BMT patients, there may be an acceleration of
the autoinfection cycle which can result in hyperinfection syn-
drome and/or disseminated strongyloidiasis increasing the high
probability of multi-organ system invasion. Treatment goals of
patients with S. stercoralis are directed toward preventing hyperin-
fection and dissemination, as well as complete eradication. Three
oral preparations are available for use in uncomplicated intestinal
strongyloidiasis, these include: thiabendazole, albendazole, and
ivermectin. Multi-dose scheduled regimens may be necessary. Ed-
ucational opportunities should focus on increasing clinician’s
knowledge about clinical manifestations, diagnosis/pathogenesis,
and treatment of this infrequent infection to facilitate earlier rec-
ognition of and/or surveillance for infection in high-risk patients.
A case study of a BMT patient will be presented.
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PATIENT ACCESS: ENHANCING THE REFERRAL PROCESS
Cruz, E.D., Kersten, B.R., Wallis, C.G., Basquez, S.H., Hsu, Y. The
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Patient Access is a vital factor in obtaining new patients and
achieving high levels of Referring Physician (RP) satisfaction in a
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clinical program. The New Patient Referral (NPR) team has been
working diligently to meet the needs of community physicians who
refer patients for blood and marrow transplantation (BMT).
In an effort to improve the referral process and increase RP
satisfaction, the BMT- NPR team collaborated with the Ofﬁce of
Physician Relations in a process improvement project which re-
sulted in the creation of a Satisfaction Survey Tool (SST). The
information obtained from the SST reﬂected the perception of the
RP on telephone courtesy, promptness and efﬁciency in returning
initial referral call and timely referral facilitation serving as the
baseline level of performance. Community physicians who have
referred a BMT patient within the previous 12 months received the
survey tool. Of the 13% returned, the overall results were positive
with areas for improvement identiﬁed. The Referral Team devel-
oped strategies based on the survey feedback: (1) customer service
training for the Referral Team performed by a consultant skilled in
physician-referral program; (2) revision of the Medical Acceptance
Criteria and policy that guides the NPR team regarding clinical
information needed for medical review; (3) development of an
algorithm on the Referral Process that includes a telephone script
for answering referrals; (4) development of a Referral Notiﬁcation
Letter that serves as a thank you note; and (5) development of an
on-line referral for physicians. The improvement strategies have
resulted in a more organized and consistent NPR process. The
staff has been encouraged by the verbal feedback of the RP regard-
ing the smooth processing of referrals. A follow-up survey will be
sent to the RP to evaluate if the improvements resulted in a positive
difference in the process as evidenced by improved communication
and ease of access.
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INFECTIOUS COMPLICATIONS OF THE GASTROINTESTINAL TRACT IN
THE ALLOGENEIC BMT PATIENT
Metoyer, L.J., Westmoreland, M.D. The University of Texas M. D.
Anderson Cancer Center, Houston, TX.
Gastrointestinal (GI) tract complications in the bone marrow
transplant patient can be a clinical challenge for both the patient
and their clinician. Although the majority of these complications
are a direct result of acute graft versus host disease, there are other
infectious etiologies that often mimic these clinical signs and symp-
toms and ultimately prove to be equally detrimental. In general,
the lack of speciﬁc pathogen identiﬁcation, adequate cultures and
deﬁnitive pathology, often prove difﬁcult, thus leaving the clinician
with uncertainty as to appropriate treatment modalities. This pre-
sentation will discuss three challenging clinical presentations of
gastrointestinal complications in the BMT patient that highlight
interesting infectious complications. Three infectious diagnoses
will be discussed in detail including pneumatosis intestinalis due to
resistant cytomegalovirus colitis, strongyloidiasis and resistant her-
pes simplex. Each case presentation will include a brief overview of
the patient demographics, the primary diagnosis, and the trans-
plant course. The primary focus of the case discussions will be on
the presentation of gastrointestinal signs and symptoms, and dif-
ferential diagnosis. Treatment options for each case as well as the
treatment course and resulting outcomes will be discussed. Speciﬁc
pharmacologic treatments of interest will include Cidofovir, Iver-
mectin, and Abendazole.
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TWO SIBLINGS IN NEED OF AN HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT): CONSIDERATIONS FOR TANDEM TRANSPLANTS
Vachon, M.-F., Lavigne, M.-J., Richer, J., Catalfamo, N., Mercier, G.,
Vandenbosch, K., Duval, M., Champagne, M.A. CHU Ste-Justine,
Montreal, QC, Canada.
In addition to the inherent stress to the patient and family,
HSCT carries a signiﬁcant transplant mortality risk. We describe
the experience of a family whose 2 of their 3 children needed a cord
blood HSCT within the next 6 months following the diagnosis of
a congenital MDS. Neither of them had been previously hospital-
ized nor exposed to a serious disease. Simultaneous or sequential
transplants were considered. Simultaneous transplants were at risk
to raise the overall difﬁculty of the experience but would shorten
the overall time period of restrictions following HSCT. Also, if the
ﬁrst of 2 planned sequential transplants had been unsuccessful,
there might have been a signiﬁcant negative impact on the family.
Also, everyone on the team was conscious of the potential risks
associated with doing two siblings at the same time (constant
comparison of the two, errors, etc.). The 2 options were discussed
with the family.
The family initially decided to proceed with sequential HSCT
but then instead chose simultaneous transplants. The HSCTs were
performed 2 days apart. The length of stay for the 4-year-old
daughter was 41 days: she fully engrafted without major compli-
cations. The 6-year-old son did not engraft and remained pancy-
topenic. A second HSCT was immediately performed: his total
stay was 105 days.
The two children are now more than 6 months post-HSCT with
Lansky scores of 100%, no evidence of GVHD and without im-
munosuppression. The parents still consider that they chose cor-
rectly in proceeding with simultaneous HSCT. However, they
recognize that it was a very difﬁcult experience. For example, they
feel that it was extremely difﬁcult to manage the family daily
routine, the preparation of the medications, and the restrictions
due to the immunosuppressed status of their children. Also, the
unexpected second HSCT needed by their son added to their
stress. They recognize that the support they received from their
extended families and the transplant team played a signiﬁcant role
in their adaptation to the situation. Among the facilitating mea-
sures implemented by the team, the children were hospitalized in
neighboring rooms sharing an anteroom. The parents were thus
able to visit both children more easily and the children were able to
visit each other.
In conclusion, if again confronted with the need to transplant 2
siblings, the most important factor to consider is the family’s
internal and external resources to face this difﬁcult and uncommon
experience.
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THE DEVELOPMENT OF THE LEAD TRANSPLANT COORDINATOR FOR
ONE OF THE LARGEST BLOOD AND MARROW TRANSPLANT CENTERS
IN THE COUNTRY
Koval, E.T., Adornetto-Garcia, D. The University of Texas M. D.
Anderson Cancer Center, Houston, TX.
A challenge for one of the largest blood and marrow transplant
centers in the country is the management of complex internal
communications associated with a highly diversiﬁed program.
With this diversiﬁcation comes a program that is divided into many
processes represented by a team of people that function as a
network to achieve a common goal. The pre-transplant phase is
one such process and is a complex, emotional experience for the
patient demanding the expertise of a BMT Coordinator Team
functioning at the center of the network. A Lead Transplant
Coordinator position was developed to provide support and lead-
ership to this team while addressing communication needs. The
Lead Transplant Coordinator functions as the team leader with
supervisory authority over 6 registered nurses and 1 assistant that
comprise the coordinator team. The supervisory role is further
divided into 5 distinct sets of responsibilities, which includes the
following: Human Resource Management, Collaboration and
Teamwork, Patient Education and Satisfaction, Stafﬁng and Pro-
fessional Education, and Regulatory Compliance including policy
and procedure review. While each coordinator is able to focus on
the coordination of care for the individual patient, the lead coor-
dinator focuses on the 5 individual sets of responsibilities and
ensures that the Coordinator Team is successfully delivering the
highest quality of professional service to both patients and col-
leagues. The lead coordinator meets on a regular basis with the
coordinator team, the program’s administrative director, medical
director, business center supervisor, and research nursing supervi-
sors to facilitate communication and collaboration amongst the
teams.
The outcome of this new structure represents the Coordinator
Team as a cohesive unit with a common set of team goals and a
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